The collateral source rule cannot be used to confer UCL standing on a plaintiff who has suffered no economic injury from the alleged unfair competition but whose insurer paid more as a result.  Here, plaintiff alleged that Genentech sole a drug in too big doses that ended up wasting the expensive drug.  Plaintiff conceded he would have paid the same insurance deductible whether or not the size of the dosage was reduced, but tried to claim standing based on the extra amounts his health insurer allegedly had to pay for the oversized doses.  Plaintiff lacked UCL standing.